Literature DB >> 5508377

The reaction mechanism of human C5 in immune hemolysis.

N R Cooper, H J Müller-Eberhard.   

Abstract

The data presented here indicate that the C5 reaction step may proceed via the specific attachment of C5 to EAC1,4,2,3 and the formation of a hemolytically active C5 intermediate complex. During this process only a minor proportion (less than 4%) of C5 offered to EAC1,4,2,3 becomes bound, although the remaining C5 also participates in the reaction as evidenced by its inactivation in the fluid phase. Once bound, C5 is exceptionally efficient in producing hemolysis, requiring less than seven specifically bound molecules per cell for the production of a hemolytic lesion. The extent of formation of the C5 intermediate complex is primarily dependent on the number of molecules of C4, 2 and C3 present on the cells employed for its generation. In these respects, the mode of action of C5 is completely analogous to that of the other components of complement thus far investigated. The C5 step differs, however, in other aspects. The binding of C5 is influenced by C6 and C7, components which are thought to act subsequent to it in the complement sequence. In addition, the hemolytic activity of the isolated C5 intermediate complex is exceedingly labile, having an average half-life at 30 degrees C of only 9 min. This characteristic distinguishes the C5 step, along with the C2 step, as potentially rate-limiting in the complement reaction. However, unlike C2, C5 remains firmly cell-bound during the decay process and apparently undergoes an alteration in situ which renders it hemolytically unreactive. Finally, C5 is unique in that it readily adsorbs in native form to unsensitized erythrocytes. This nonspecifically bound C5 remains firmly attached, although it may be specifically utilized as a source of C5 by an ongoing complement reaction. The significance of the marked affinity of native C5 for cell-surface receptors remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5508377      PMCID: PMC2138854          DOI: 10.1084/jem.132.4.775

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  18 in total

1.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

2.  Studies on the mode of action of the fifth, sixth and seventh component of human complement in immune haemolysis.

Authors:  U R Nilsson; H J Müller-Eberhard
Journal:  Immunology       Date:  1967-07       Impact factor: 7.397

3.  Separation and partial purification of the sixth, seventh and eighth components of human haemolytic complement.

Authors:  U Nilsson
Journal:  Acta Pathol Microbiol Scand       Date:  1967

4.  C'2ad, an inactive derivative of C'2 released during decay of EAC'4,2a.

Authors:  R M Stroud; M M Mayer; J A Miller; A T McKenzie
Journal:  Immunochemistry       Date:  1966-05

5.  Complement associated peptidase activity of guinea pig serum. I. Role of complement components.

Authors:  N R Cooper; E L Becker
Journal:  J Immunol       Date:  1967-01       Impact factor: 5.422

6.  Hemolytic activity of lipoprotein-depleted serum and the effect of certain anions on complement.

Authors:  A P Dalmasso; H J Müller-Eberhard
Journal:  J Immunol       Date:  1966-11       Impact factor: 5.422

7.  Enharncement of the hemolytic activity of the second component of human complement by oxidation.

Authors:  M J Polley; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1967-12-01       Impact factor: 14.307

8.  The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement.

Authors:  C G Cochrane; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1968-02-01       Impact factor: 14.307

9.  Mouse complement: the effect of sex hormones and castration on two of the late-acting components.

Authors:  W H Churchill; R M Weintraub; T Borsos; H J Rapp
Journal:  J Exp Med       Date:  1967-04-01       Impact factor: 14.307

10.  The reaction mechanism of beta-1C-globulin (C'3) in immune hemolysis.

Authors:  H J Müllerèberhard; A P Dalmasso; M A Calcott
Journal:  J Exp Med       Date:  1966-01-01       Impact factor: 14.307

View more
  62 in total

1.  Crystal structure of C5b-6 suggests structural basis for priming assembly of the membrane attack complex.

Authors:  Alexander E Aleshin; Richard G DiScipio; Boguslaw Stec; Robert C Liddington
Journal:  J Biol Chem       Date:  2012-04-12       Impact factor: 5.157

Review 2.  Complement activation in the context of stem cells and tissue repair.

Authors:  Ingrid U Schraufstatter; Sophia K Khaldoyanidi; Richard G DiScipio
Journal:  World J Stem Cells       Date:  2015-09-26       Impact factor: 5.326

3.  Importance of the third thrombospondin repeat of C6 for terminal complement complex assembly.

Authors:  R Würzner; D Mewar; B A Fernie; M J Hobart; P J Lachmann
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

Review 4.  How novel structures inform understanding of complement function.

Authors:  Elena Goicoechea de Jorge; Hugo Yebenes; Marina Serna; Agustín Tortajada; Oscar Llorca; Santiago Rodríguez de Córdoba
Journal:  Semin Immunopathol       Date:  2017-08-14       Impact factor: 9.623

5.  The cytolytic C5b-9 complement complex: feedback inhibition of complement activation.

Authors:  S Bhakdi; F Maillet; M Muhly; M D Kazatchkine
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

6.  Prevention of immune precipitation by purified components of the alternative pathway.

Authors:  J K Naama; E Holme; E Hamilton; K Whaley
Journal:  Clin Exp Immunol       Date:  1985-04       Impact factor: 4.330

7.  Activation of human complement by human lymphoid cells sensitized with histocompatibility alloantisera.

Authors:  S Ferrone; N R Cooper; M A Pellegrino; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1973-12       Impact factor: 11.205

8.  Interaction of complement components with a serum-resistant strain of Salmonella typhimurium.

Authors:  B L Reynolds; U A Rother; K O Rother
Journal:  Infect Immun       Date:  1975-05       Impact factor: 3.441

9.  Mechanism of resistance to complement-mediated killing of bacteria encoded by the Salmonella typhimurium virulence plasmid gene rck.

Authors:  E J Heffernan; S Reed; J Hackett; J Fierer; C Roudier; D Guiney
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

10.  Effect on the human complement system of the major non-steroidal anti-inflammatory drugs: aspirin, indomethacin, phenylbutazone, oxyphenbutazone and sulindac.

Authors:  J O Minta; M B Urowitz; H A Smythe; D E Isenman
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.